Liminatus Pharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LIMN Nasdaq 2836 liminatuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Liminatus Pharma, Inc.

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation - Oct 30th, 2025 8:04 am
BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism - Aug 5th, 2025 10:11 am
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies - Jul 25th, 2025 6:31 am
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy - Jul 24th, 2025 6:31 am
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy - Jul 22nd, 2025 11:30 am